First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2026 revenue reaching $1.5B — +8.8% growth in a single year.
What Moves the Stock
1Neuromodulation implant volumes and market penetration in treatment-resistant depression (TRD) indication, currently <5% penetrated market
2Cardiac surgery procedure volumes globally, particularly in Europe (40% of revenue) and US (35% of revenue), which correlate with elective surgery rates
3New product launches: Advanced Connect 3D heart-lung machine adoption, next-generation VNS devices with extended battery life
4Reimbursement decisions for VNS Therapy in depression from CMS and European payers, critical for TRD market expansion
5Margin expansion initiatives in Cardiovascular segment through manufacturing consolidation and product mix shift to premium disposables
6Cardiovascular segment (~65-70% of revenue): heart-lung machines, oxygenators, perfusion disposables sold to cardiac surgery centers globally
7Neuromodulation segment (~30-35% of revenue): VNS Therapy implantable pulse generators and leads for epilepsy and depression, recurring revenue from device replacements every 5-8 years
8Service and consumables: recurring revenue from disposable perfusion products and device monitoring
growth - Investors focus on Neuromodulation segment's expansion potential in underpenetrated TRD market (estimated $3B+ opportunity)…
Rising rates have modest negative impact through two channels: (1) Hospital capital budgets tighten as borrowing costs increase…
Watch on earnings: US and European elective cardiac surgery procedure volumes (proxy: hospital admissions data, cardiac catheterization rates), VNS Therapy new patient implants per quarter and active patient base size, FDA approval timelines for expanded Neuromodulation indications (TRD label expansion, obesity trials).
One Sentence Summary:
LivaNova: the story is balanced — neuromodulation implant volumes and market penetration in treatment-resistant depression (trd) indication, currently <5% penetrated market.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.